Cybin Inc. (HELP)
| Market Cap | 743.19M +314.4% |
| Revenue (ttm) | n/a |
| Net Income | -171.20M |
| EPS | -4.05 |
| Shares Out | 61.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,524,729 |
| Open | 11.55 |
| Previous Close | 11.45 |
| Day's Range | 11.11 - 12.03 |
| 52-Week Range | 3.76 - 12.03 |
| Beta | 0.56 |
| Analysts | Strong Buy |
| Price Target | 35.53 (+196.58%) |
| Earnings Date | Aug 14, 2026 |
About HELP
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company’ preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central ne... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for HELP stock is "Strong Buy." The 12-month stock price target is $35.53, which is an increase of 196.58% from the latest price.
News
Cybin Earnings release: Q1 2027
Cybin released its Q1 2027 earnings on August 14, 2026, summarizing the period's financial results.
Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights
- Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization -
Cybin Transcript: Canaccord Genuity's 46th Annual Growth Conference
A new CEO with deep CNS experience outlined a vision focused on execution and innovation in mental health. The lead candidate, HLP003, showed strong phase II results and is nearing phase III data, while a broad pipeline and robust IP position the company for future growth.
Helus Pharma Appoints Michael Halstead as Chief Executive Officer
Former President of Intra-Cellular Therapies, Inc. was instrumental in building and scaling the company, which was subsequently acquired by Johnson & Johnson
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program Participant rollover is ongoing into the EXTEND long-term study generating long-term safety and durability dat...
Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
- Recently closed $50 million underwritten offering reinforces strong institutional investor conviction and bolsters balance sheet for execution of second Phase 3 HLP003 trial 1 , 2 ,3 , EMBRACE, for ...
Cybin Annual report: Q4 2026
Cybin has published its Q4 2026 annual report on June 29, 2026.
Cybin Earnings release: Q4 2026
Cybin released its Q4 2026 earnings on June 29, 2026, summarizing the period's financial results.
Cybin Slides: Corporate presentation
Cybin has posted slides in relation to its latest quarterly earnings report, which was published on June 29, 2026.
Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering
NEW YORK and TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical stage pharmaceutical company committed to helping min...
Helus Pharma™ Announces US$50 Million Underwritten Offering
NEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical stage pharmaceutical company committed to helping min...
Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress
- APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorder (“MDD”) is progressing as planned and has surpassed 86% enrollment -
Cybin Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference
The summit featured updates on novel serotonergic agonists for MDD and GAD, with HLP003 in phase III and top-line data expected by year-end. The company leverages established psychiatric infrastructure and maintains strong FDA engagement, targeting NDA submission in 2028.
Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference
NEW YORK and TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Helus PharmaTM (Nasdaq: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serot...
Cybin Transcript: Jefferies Global Healthcare Conference 2026
The company is advancing novel serotonergic agonists for mental health, with a lead MDD program showing strong efficacy and durability, and a second program targeting anxiety. Regulatory support is robust, commercialization prospects are strong due to unique dosing and IP, and key phase III data is expected in Q4.
Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York
Eric So, Interim CEO, to participate in a fireside chat on Thursday, June 4 at 2:35 p.m. EDT NEW YORK and TORONTO, June 01, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a cli...
CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
NEW YORK & TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline on April 28, 2026, by Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP), please note references to Veterans...
Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference
Eric So, Interim CEO, to appear on panel entitled “The Next Wave of Health Innovation,” on May 4, 2026 NEW YORK and TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: H...
Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
NEW YORK & TORONTO, April 28, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel seroton...
Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan
NEW YORK and TORONTO, April 23, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serot...
How Trump's psychedelics executive order could unlock stalled cannabis reform
The White House psychedelics executive order accelerates research, clinical trials and "Right to Try" access for drugs like psilocybin, MDMA and ibogaine. The order does not change their legal status,...
Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions
NEW YORK and TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serot...
Helus Pharma Announces Chief Executive Officer Transition; Eric So to Resume Role as Interim Chief Executive Officer
This news release constitutes a “designated news release” for the purpose of the Company's prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 20...
Psychedelic drug makers rally as Trump orders FDA to expedite reviews
Shares of psychedelic drug developers rose in premarket trading on Monday after U.S. President Donald Trump signed an executive order directing health regulators to speed up reviews of psychedelic dr...
Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs
NEW YORK and TORONTO, April 16, 2026 (GLOBE NEWSWIRE) -- Helus PharmaTM (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel sero...